Medical Doctor Program year 2025 Source: CMS Open Payments, 2026 publication

Fernando Tondato

Clinical Cardiac Electrophysiology Albuquerque, NM Medical Doctor

NPI 1205048071 CMS profile 326045

502 Elm St Ne, Albuquerque, NM 87102

Open in the dashboard

General payments

$39

2 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fernando Tondato of Albuquerque, NM is reported in the CMS Open Payments database as having received $39 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 1st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $39 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fernando Tondato
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Fernando Tondato were reported at $39. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Fernando Tondato Clinical Cardiac Electrophysiology median Middle half National median
2019 $0 $2,361 $585–$8,260 $163
2020 $0 $993 $247–$4,351 $114
2021 $0 $1,185 $326–$4,739 $132
2022 $0 $2,073 $554–$6,789 $149
2023 $0 $2,568 $759–$8,159 $160
2024 $0 $2,557 $703–$7,403 $164
2025 $39 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program year 2025
  1. Cordis US Corp. $21 1 payment
  2. Boston Scientific Corporation $18 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $39 2 payments
Products named General payments · program year 2025
  1. MYNX CONTROL VENOUS $21 1 payment
  2. General - Tachy $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

583

Median for Cardiology: 2,533

Drug cost

$77,609

Median for Cardiology: $485,213

Branded share of claims

21.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 24 $26,372
Eliquis Apixaban Brand 13 $25,379
Pradaxa Dabigatran Etexilate Mesylate Brand 50 $12,754
Flecainide Acetate Generic 198 $6,068
Amiodarone Hcl Generic 121 $2,993
Dofetilide Generic 14 $1,294
Metoprolol Succinate Generic 53 $861
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 27 $684
Sucralfate Generic 17 $456
Metoprolol Tartrate Generic 42 $391

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$2,543

Medicare's payments for the services billed

Medicare patients

21

Average age 71

Services billed

27

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 52%
Chronic kidney disease 52%
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record